company background image
XAIR

Beyond AirNasdaqCM:XAIR Stock Report

Market Cap

US$278.8m

7D

-0.8%

1Y

123.0%

Updated

27 Sep, 2021

Data

Company Financials +
XAIR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

XAIR Overview

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems.

Price History & Performance

Summary of all time highs, changes and price drops for Beyond Air
Historical stock prices
Current Share PriceUS$11.64
52 Week HighUS$4.62
52 Week LowUS$12.87
Beta-0.48
1 Month Change2.20%
3 Month Change74.25%
1 Year Change122.99%
3 Year Change180.48%
5 Year Changen/a
Change since IPO86.24%

Recent News & Updates

Shareholder Returns

XAIRUS Medical EquipmentUS Market
7D-0.8%-0.8%2.0%
1Y123.0%32.6%32.8%

Return vs Industry: XAIR exceeded the US Medical Equipment industry which returned 32.6% over the past year.

Return vs Market: XAIR exceeded the US Market which returned 32.8% over the past year.

Price Volatility

Is XAIR's price volatile compared to industry and market?
XAIR volatility
XAIR Beta-0.48
Industry Beta0.88
Market Beta1

Stable Share Price: XAIR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: XAIR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a41Steve Lisihttps://www.beyondair.net

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union.

Beyond Air Fundamentals Summary

How do Beyond Air's earnings and revenue compare to its market cap?
XAIR fundamental statistics
Market CapUS$278.75m
Earnings (TTM)-US$22.88m
Revenue (TTM)US$644.03k

432.9x

P/S Ratio

-12.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XAIR income statement (TTM)
RevenueUS$644.03k
Cost of RevenueUS$0
Gross ProfitUS$644.03k
ExpensesUS$23.52m
Earnings-US$22.88m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.96
Gross Margin100.00%
Net Profit Margin-3,551.98%
Debt/Equity Ratio14.5%

How did XAIR perform over the long term?

See historical performance and comparison

Valuation

Is Beyond Air undervalued compared to its fair value and its price relative to the market?

8.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XAIR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: XAIR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XAIR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XAIR is overvalued based on its PB Ratio (8.3x) compared to the US Medical Equipment industry average (4.7x).


Future Growth

How is Beyond Air forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

56.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XAIR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XAIR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XAIR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XAIR's revenue (66.4% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: XAIR's revenue (66.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XAIR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Beyond Air performed over the past 5 years?

-27.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XAIR is currently unprofitable.

Growing Profit Margin: XAIR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XAIR is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.

Accelerating Growth: Unable to compare XAIR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XAIR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).


Return on Equity

High ROE: XAIR has a negative Return on Equity (-68.39%), as it is currently unprofitable.


Financial Health

How is Beyond Air's financial position?


Financial Position Analysis

Short Term Liabilities: XAIR's short term assets ($41.0M) exceed its short term liabilities ($4.5M).

Long Term Liabilities: XAIR's short term assets ($41.0M) exceed its long term liabilities ($6.2M).


Debt to Equity History and Analysis

Debt Level: XAIR's debt to equity ratio (14.5%) is considered satisfactory.

Reducing Debt: XAIR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XAIR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XAIR has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 41.4% each year.


Dividend

What is Beyond Air current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XAIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XAIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XAIR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XAIR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XAIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Steve Lisi (50 yo)

4.25yrs

Tenure

US$1,538,000

Compensation

Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD1.08M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: XAIR's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: XAIR's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XAIR insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.7%.


Top Shareholders

Company Information

Beyond Air, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Beyond Air, Inc.
  • Ticker: XAIR
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$278.753m
  • Shares outstanding: 23.95m
  • Website: https://www.beyondair.net

Number of Employees


Location

  • Beyond Air, Inc.
  • 825 East Gate Boulevard
  • Suite 320
  • Garden City
  • New York
  • 11530
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 23:06
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.